GlaxoSmithKline Races to Develop Bioelectronic Medicines with New Venture Fund
By m rochan | August 9, 2013 12:35 AM EST
British drugmaker GlaxoSmithKline will increase its focus on bioelectronic medicines with a new venture capital fund, mandated to invest in companies developing the so-called "medicines of the future".
The $50m (£32m, €37m) fund - called Action Potential Venture Capital - will complement the work of GSK's bioelectronics research division, created last year. It will invest in five to seven companies over the next five years, GSK said in a statement on Thursday.
Britain's biggest drugmaker hopes to have the first medicine that "speaks the electrical language of the [human] body" ready for approval by 2020.
The fund's first investment would be in SetPoint Medical, a US-based firm developing small implantable devices to treat inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis.
Bioelectronic medicine refers to tiny implants capable of emitting electrical impulses to treat various diseases. These implants can read patterns of electronic signals in nerves, which can be irregular in patients suffering from a disease.
"We want to help create the medicines of the future and be the catalyst for this work," said Moncef Slaoui, chairman of R&D and the architect of GSK's early stage investment strategy.
"GSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts," he said.
The venture fund will be based in the US, in Cambridge, Massachusetts.
Bioelectronic medicine is not entirely new. Electrical devices such as heart pacemakers have been used for many years. Electrical stimulation has been used to treat Parkinson's disease and some neurological disorders.
GSK investigation in China
GSK has been facing investigation in China into alleged malpractice by its executives.
China's Ministry of Public Security has accused unnamed GSK executives of routing 3bn yuan (£324m, €375m, $489m) in bribes to doctors through 700 travel agencies and consultancies over six years.
GSK admitted that some Chinese executives appeared to have broken the law, but CEO Andrew Witty said that their head office had no prior knowledge about the wrongdoing.
In a bid to repair its tainted image in connection with the scandal, the company appointed Herve Gisserot, senior vice-president for Europe, as the new chief of its China operations.
He replaces Mark Reilly as general manager of China operations.
To contact the editor, e-mail:
Most Popular Slideshows
- Typhoon Rammasun Claims 18 Lives in China, Incurs $4.32B Losses (PHOTOS)
- Kate Middleton's Pregnancy Hearsays: Possible Evidence Revealed [PHOTOS]
- Selena Gomez Turns 22 Today, Celebrates Early without Justin Bieber: Top 12 Interesting Facts About the Singer [SEE PHOTOS]
Join the Conversation
- Malaysian Airlines Flight 17: Air Carrier to Give $5,000 Assistance to Victims’ Families; Bankruptcy Looms as 2 Air Mishaps Would Cost Firm Minimum $80.55 M Compensation
- Foxconn And Pegatron Corp Readies For Apple's iPhone 6 Mass Production This Month
- KFC & McDonald’s Accused of Serving ‘Expired’ Meat to Customers
- Malaysian Airlines Ukraine Tragedy Hits Asian Stock Markets
- California Fruits Recalled in USA and Canada for Possible Listeria Contamination
- Motorola Moto G Vs. Xiaomi Mi3 – Low in Price, High -level Features
- Google Nexus 8 Release Date Soon Along with 2 More HTC Android Tablets – Reports
- Sony PlayStation 4 Outsells a Resurgent Xbox One in June
- Killer Xiaomi Mi4 at $369 Likely to Come With 5.0-Inch Display, Snapdragon 801 Processor, 3GB RAM and More
- NVIDIA Shield Gaming Tablet with Tegra K1 SoC Reported to be Released on July 29
- BlackBerry Passport Video Leak, Release Date, Five Fresh Features to Anticipate [Watch YouTube Clip] --Reports
- Iphone 6 Release Date Fast -Approaching, Reuse and Recycle Program Now in Australia